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Abstract Dipeptidyl peptidase IV (DPP IV) is a member of the
prolyl oligopeptidase family and modifies the biological activities
of certain chemokines and neuropeptides by cleaving their N-
terminal dipeptides. This paper reports the identification and
possible significance of a novel conserved sequence motif Asp-
Trp-(Val/Ile/Leu)-Tyr-Glu-Glu-Glu (DW(V/I/L)YEEE) in the
predicted L propeller domain of the DPP IV-like gene family.
Single amino acid point mutations in this motif identified two
glutamates, at positions 205 and 206, as essential for the enzyme
activity of human DPP IV. This observation suggests a novel role
in proteolysis for residues of DPP IV distant from the Ser-Asp-
His catalytic triad.
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1. Introduction
Dipeptidyl peptidase IV (DPP IV; EC 3.4.14.5) is a ubiq-
uitous type II multifunctional cell surface protein with a di-
peptidyl peptidase enzyme activity. DPP IV enzyme activity
speci¢cally cleaves dipeptides from the N-terminus of peptides
with a Pro, Hyp or Ala in the penultimate position. Proline,
due to its cyclic nature, is a unique amino acid that imposes
structural restrictions on peptides and proteins in which it is
found. Consequently, proline appears to be near the N-termi-
nus of many biologically active proteins and plays a key phys-
iological role in the protection of these molecules against en-
zymatic cleavage by aminopeptidases [1]. DPP IV substrates
include certain chemokines, growth factors (e.g. growth hor-
mone, growth hormone-releasing factor, glucagon-like pep-
tides 1 and 2) and neuro- and vasoactive peptides including
neuropeptide Y, peptide YY and substance P. The N-terminal
truncation of the chemokines RANTES (regulated on activa-
tion normal T-cell expressed and secreted), eotaxin, macro-
phage-derived chemokines and stromal cell-derived factor-1K
has been found to reduce their chemotactic activity and im-
pair mobilisation of intracellular Ca2 through their respec-
tive chemokine receptors [2^5]. However, these DPP IV-trun-
cated chemokines maintain their ability to inhibit HIV-1 in-
fection via the various chemokine receptors.
DPP IV is a non-classical serine protease as its catalytic
residues are arranged in the unique order Ser-Asp-His. This
order is the reverse of that found in classical serine proteases
such as the trypsin and subtilisin families [6]. The 200 C-ter-
minal residues of DPP IV (containing the catalytic triad) have
homology with several other non-classical serine hydrolases
including the prolyl oligopeptidases and the acylaminoacyl
peptidases. These enzymes have been classi¢ed as members
of the prolyl oligopeptidase (POP) family [7,8]. While mem-
bers of this family have di¡erent substrate speci¢cities, they
use similar structural features to form their catalytic domains.
All members of the POP family are predicted to contain an
K/L hydrolase fold [6,9,10]. The three dimensional structures
of proline iminopeptidase from Xamanthomas campestris pv.
Citri (EC 3.5.11.5) [11] and POP (EC 3.4.21.26) [12] have been
solved. Both of these structures contain an K/L hydrolase fold.
The structure of the N-terminal regions of DPP IV and other
members of the POP family are unknown but could include
an atypical L propeller domain of four-stranded L sheets as
occurs in POP [12] (Abbott et al., 1999, submitted).
DPP IV homologues have been cloned from other mam-
mals [13,14], yeast (Schizosaccharomyces pombe and Saccha-
romyces cerevisiae) [15,16], the fungus Aspergillus oryzae,
Xenopus laevis [17], Flavobacterium meningosepticum [18] and
Caenorhabditis elegans [19]. Other mammalian members of the
POP family that share striking sequence homology with DPP
IV are the dipeptidyl aminopeptidase short and long forms
(DPPX-s and DPPX-l) [20,21] and ¢broblast activation pro-
tein (FAP) [22,23]. Due to two substitutions in the serine
recognition site, DPPX has no enzyme activity [24], whereas
FAP has both a dipeptidyl peptidase and gelatinase activity
[25^27]. We suggest that these molecules form a distinct sub-
class of the POP family, a DPP IV-like gene family that in-
cludes FAP and DPPX.
Our characterisation of the human DPP IV gene structure
[28] enabled us to use each exon as an independent unit to
search the protein sequence databases. This analysis revealed
that a region of human DPP IV exons 8 and 9 is highly
conserved within members of the DPP IV-like gene family.
We observed within this region a conserved sequence motif
Asp-Trp-(Val/Ile/Leu)-Tyr-Glu-Glu-Glu (DW(V/I/L)YEEE).
This motif is found in the N-terminal region of DPP IV,
FAP and DPPX of all the above-mentioned species distant
from the C-terminal region that contains the catalytic triad
residues. We hypothesised that since this motif is highly con-
served between species and within members of the DPP IV-
like gene family, it is involved in the dipeptidyl peptidase
activity of these proteins. The aim of this present study was
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to investigate the role of residues found in this novel sequence
motif in the enzyme activity of DPP IV.
2. Materials and methods
2.1. Materials
Cell culture reagents were purchased from Trace Biosciences (Syd-
ney, Australia), culture £asks were from Nunc (Naperville, IL, USA).
NuPage electrophoresis reagents were obtained from Novex (San Die-
go, CA, USA) and nitrocellulose from Schleicher and Schuell (Dassel,
Germany). All other reagents including DPP IV substrates and ad-
enosine deaminase (ADA) were from Sigma (St. Louis, MO, USA).
Visualisation of immune complexes after Western blotting used chem-
iluminescence with Supersignal (Pierce, Rockford, IL, USA) and
BIOMAX ML ¢lm (Kodak, Rochester, NY, USA).
The cDNA for wild-type DPP IV, ptzCD26.11, was a gift from Dr.
Chikao Morimoto (Dana Farber Center, Boston, USA) [29]. The
monoclonal antibody (mAb) against DPP IV, EF6/B10 [30] and the
rabbit anti-ADA antiserum were gifts from Dr. Thilo Ka«hne and
mAb 2A6 was a gift from Professor Sibrand Poppema [31,32].
2.2. Bioinformatics
Basic local alignment search tool (BLAST) programs [33^35] and
all multiple sequence alignments were performed through the Austra-
lian National Genomic Information Service (ANGIS, Sydney,
Australia). BLAST protein (BLASTP) searched non-redundant
PDB, SwissProt, PIR and GenPept databases. PileUp (GCG Version
8, Genetics Computer Group, Madison, WI, USA) was used for
multiple sequence alignments of the amino acids of DPP IV, FAP
and DPPX proteins.
2.3. Preparation of DPP IV mutants
Full length DPP IV cDNA was excised with XbaI from ptzCD26.11
and ligated into the transient expression vector pEF-BOS [36]. Point
mutations were performed in the pEF-BOS/DPP IV construct using a
Quick Change Mutagenesis kit (Stratagene, La Jolla, CA, USA).
Eight mutant plasmids were prepared using the appropriate oligonu-
cleotides to direct mutagenesis as listed in Table 1. The mutagenic
oligonucleotides were purchased from GeneWorks (Adelaide, Austra-
lia). After mutagenesis, plasmid DNA was prepared using either a
RPM kit (BIO 101, Vista, CA, USA) or a QIAGEN kit (Hilden,
Germany). Introduced point mutations were veri¢ed using automated
sequencing with £uorescent dideoxy terminators (SUPAMAC, Syd-
ney, Australia).
2.4. Transient expression of DPP IV mutants
Monkey kidney ¢broblast, COS-7 cells (ATCC, CRL-1651), were
grown in Dulbecco’s MEM medium supplemented with 10% foetal
calf serum and 2 mM glutamine. For £ow cytometry and Western
blot analysis, COS-7 cells were transfected in a subcon£uent 75 cm2
£ask using 15 Wg DNA and 48 Wl Fugene-6 (Roche, Palo Alto, CA,
USA) following the manufacturer’s instructions.
2.5. Cytochemistry
COS-7 cells grown on chamber slides (Labtek II, Naperville) were
¢xed in cold ethanol prior to staining for DPP IV enzyme activity,
binding to biotinylated ADA or binding to anti-DPP IV mAb EF6/
B10 [27,37,38]. ADA (type VI, Sigma) was coupled to sulfosuccini-
midyl-6-(biotinamido) hexanoate (biotinylated) or to £uorescein iso-
thiocyanate (FITC) by standard methods [37].
2.6. DPP IV enzyme assay
DPP IV enzyme assays were performed on trypsin/EDTA-harvested
COS-7 cells 72 h after transfection and used Gly-Pro-p-nitroanilide-p-
toluene sulfonate salt as the substrate [39]. Transfected cells were
suspended at 20 000 cells per well in 70 Wl Hanks bu¡er (Trace Bio-
sciences, Australia), pH 7.0, and incubated for 30 min at 19‡C. Ab-
sorbances at 690 nm were subtracted from absorbances at 405 nm to
increase the speci¢city of measurements. Analyses of Michaelis Ment-
en kinetics used KaleidaGraph v. 3.08 (Synergy Software, Reading,
PA, USA). Assays were performed in triplicate on two transfections.
Statistical analysis used Student’s t test.
2.7. Flow cytometry
Suspensions of trypsin/EDTA-harvested COS-7 cells were stained
using £uorescein-conjugated ADA (ADA-FITC) and anti-DPP IV
mAb EF6/B10 followed by goat anti-mouse Ig phycoerythrin (PE)
(Caltag, Burlingame, CA, USA) and analysed on a FACScan
(Becton Dickinson) [38]. Forward scatter and right angle scatter
were used to establish gate 1, which excluded non-viable cells and
aggregates of cells. Isotype-matched controls were used in each experi-
ment and positive controls were included for adjustment of compen-
sation.
2.8. Western Blotting
COS-7 cell membranes were prepared and Western blotting was
performed as described previously [27] except that non-boiled samples
were run on either 8^12% NuPAGE (Novex) or 8% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Gradipore,
N.S.W., Australia) gels and transferred to nitrocellulose as per the
manufacturer’s instructions. Soluble recombinant human DPP IV
used as a marker was puri¢ed from a stable DPP IV expressing cell
line [40]. DPP IV was detected using mAb 2A6 and horseradish per-
oxidase (HRP)-conjugated rabbit anti-mouse Ig, catalogue number
P0260 (Dako, Santa Barbara, CA, USA). The ADA overlay blot
used 40 Wg/ml ADA type VIII, rabbit anti-ADA antiserum (1/1500)
and donkey anti-rabbit HRP (1/1500, Amersham, Buckinghamshire,
UK). The ADA appeared as a single band at 43 kDa upon both SDS-
PAGE and Western blot and the ADA antiserum bound only the
expected 43 kDa band on Western blots, indicating purity of the
ADA preparation and mono-speci¢city of the antiserum (data not
shown).
3. Results
3.1. BLASTP searches and multiple sequence alignments
revealed a DPP IV-like gene family with a novel conserved
sequence motif Asp-Trp-(Val/Ile/Leu)-Tyr-Glu-Glu-Glu
(DW(V/I/L)YEEE)
Sequence comparisons can help in understanding how se-
quences and hence proteins have evolved. Protein database
searches identi¢ed a distinct sub-class of the POP family, a
DPP IV-like gene family that included mammalian, bacterial,
yeast, fungal, X. laevis and C. elegans DPP IV, FAP and
DPPX. The characterisation of the exon structure of human
DPP IV [28] enabled BLAST searches of the combined pro-
tein databases with the amino acids of each exon as discrete
units of input. The major purpose of these searches was to
Table 1
The amino acid and base substitutions of each point mutation
Name of mutation Type of substitution Base pair changes
pEF-BOS/DPPIVTrp201Tyr NPDP Trp (TGG)DTyr (ATG)
pEF-BOS/DPPIVVal202Arg NPDB Val (GTT)DArg (CGT)
pEF-BOS/DPPIVVal202Ala NPDNP Val (GTT)DAla (GCT)
pEF-BOS/DPPIVTyr203Val PDNP Tyr (TAT)DVal (GTT)
pEF-BOS/DPPIVGlu204Lys ADB Glu (GAA)DLys (AAA)
pEF-BOS/DPPIVGlu204Gln ADP Glu (GAA)DGln (CAA)
pEF-BOS/DPPIVGlu205Lys ADB Glu (GAG)DLys (AAG)
pEF-BOS/DPPIVGlu206Leu ADNP Glu(GAA)DLeu (CTA)
NP = non-polar, P = uncharged polar, A = acidic, B = basic.
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identify small regions of homology between human DPP IV
and other members of the DPP IV-like gene family. Each
BLASTP search produced a list of accession numbers and
names of sequences that satis¢ed the various thresholds of
the program. The most striking result of these searches was
that DPP IV exons 8 and 9 consistently achieved signi¢cant
BLASTP scores with each member of the DPP IV-like gene
family. Human DPP IV exons 8 and 9 had 29^52% amino
acid identity and 45^71% amino acid similarity with similar
regions in these proteins. DPP IV exons 20^26 contain the
last 200 C-terminal residues including the catalytic residues
and these were the only other exons to achieve these levels
of homology. This result led us to predict that residues in
DPP IV exons 8 and 9 are important for dipeptidyl pepti-
dase activity in the DPP IV-like gene family. Analysis of se-
quence alignments (Fig. 1) led us to focus on a highly con-
served motif Asp200-Trp201-Val202-Tyr203-Glu204-Glu205-Glu206
(DWVYEEE), which lies across the exon 8/exon 9 boundary
in human DPP IV.
3.2. Certain substitutions in the conserved motif
Asp200-Trp201-Val202-Tyr203-Glu204-Glu205-Glu206 in£uence
the enzyme activity of DPP IV
Two point mutations, Glu-205-Lys and Glu-206-Leu, spe-
ci¢cally ablated DPP IV enzyme activity, shown by enzyme
cytochemistry (Table 2) and enzyme assays of live cell suspen-
sions (Table 3 and Fig. 2). These two mutants showed no
enzyme activity by whole-cell cytochemistry and little activity
in enzyme assays of cell surface-expressed DPP IV. The £ow
cytometry and Western blot data (see below) indicated that
similar quantities of mutant and wild-type DPP IV proteins
were present in these assays, suggesting that the small Vmax of
these mutants compared to wild-type DPP IV was due to the
Fig. 1. Multiple sequence alignment of exons 8 and 9 of DPP IV with other members of the DPP IV-like gene family reveals a conserved motif
Asp200-Trp201-Val202-Tyr203-Glu204-Glu205-Glu206 (DWVYEEE). GCG PileUp of DPP IV exons 8 and 9 (residues 165^258) with mammalian, X.
laevis, bacterial, yeast, fungal and C. elegans DPP IV and DPP IV-like molecules FAP and DPPX. The shading represents residues that are ho-
mologous in 80% or more of sequences. The conserved sequence motif is boxed. The GenPept accession numbers for these sequences are:
hdpp4, human DPP IV (g180083); mdpp4, mouse DPP IV (g550375); rdpp4, rat DPP IV (g204464); xdpp4, X. laevis DPP IV (g1621279);
cdpp799, C. elegans DPP IV (g4038512); hdppxs, human DPPX short form (DPPXs, g306708); rdppxs, rat DPPXs (g408716); bdppxs, bovine
DPPXs (g408720); hfap, human FAP (g1888316); mfap, mouse FAP (g1743330); xfap, X. laevis FAP (g1314314); ydpab841, 841 amino acids
yeast gene for DPP B (g3660); ydpab818, 818 amino acids DPP B (g500698); yeast DPP A (g347197); aodpp4, A. oryzae DPP IV (g2924305);
fmdpp4, F. meningosepticum DPP IV (g577284); sc793, S. pombe 793 amino acids DPP (g3395554); sc743, S. pombe 743 amino acids DPP
(g2330688).
Table 2
DPP IV enzyme cytochemistry, mAb EF6/B10 immunocytochemis-
try and biotinylated ADA cytochemistry of transiently transfected
COS-7 cells
Mutation Enzyme stain mAb binding ADA binding
DPP IV wild-type ++ ++ ++
Trp-201-Tyr ++ ++ ++
Val-202-Arg None + None
Val-202-Ala ++ ++ ++
Tyr-203-Val ++ ++ ++
Glu-204-Lys + ++ ++
Glu-204-Gln + ++ ++
Glu-205-Lys None ++ ++
Glu-206-Leu None ++ ++
Glu-205-Lys and Glu-206-Leu di¡ered from wild-type only with
respect to DPP IV enzyme cytochemistry. In contrast, Val-202-Arg
poorly bound mAb and ADA binding was undetectable, suggesting
a defective structure. Staining intensity equivalent to wild-type
human DPP IV was scored as ++. ‘None’ indicates that no speci¢c
reaction product was detected.
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impaired function of the enzyme. The Glu-205-Lys mutation
introduced a charge reversal whilst Glu-206-Leu, the most
dramatic substitution in this mutation study, was a change
to the residue found in the equivalent position in X. laevis
FAP [41]. The Val-201-Arg mutant ablated DPP IV enzyme
activity (Table 2) but this was due to a defective structure of
the expressed protein (see Section 3.3). A mutation designed
to reverse the charge at an adjacent glutamic acid residue,
Glu-204-Lys, did not signi¢cantly alter Vmax or Km (Table
3). The other mutations, Trp-201-Tyr, Val-202-Ala, Tyr-203-
Fig. 2. Enzyme kinetics. Plots of kinetic analyses of suspensions of live cells transfected with wild-type or mutant human DPPIV constructs
Glu-205-Lys or Glu-206-Leu. Means and S.D.s of the absorbance change per minute are shown. Curve ¢tting assumed Michaelis Menten ki-
netics.
Fig. 3. Cell surface expression and ADA binding of transfected COS-7 cells. COS-7 cells transfected with wild-type (a) or mutant (c^h) DPP
IV constructs were stained by two-colour cell surface immuno£uorescence and analysed by £ow cytometry. The green (ADA-FITC; axis) and
red (anti-DPP IV mAb EF6/B10 followed by anti-mouse Ig PE; abscissa) £uorescence intensities of each event are shown. Crosshairs indicate
the boundary between non-speci¢c and speci¢c £uorescence intensities, con¢rmed by inclusion of single colour and isotype-matched negative
controls (data not shown). The mutants (d^h) including the two mutations that ablate enzyme activity, Glu-205-Lys (g) and Glu-206-Leu (h),
bound to both mAb EF6/B10 and ADA-FITC. In contrast, mutant Val-202-Arg (c) weakly bound mAb EF6/B10 but did not bind to ADA
and was thus considered to have a defective structure. The negative control was untransfected COS-7 cells (b).
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Val and Glu-204-Gln, were not detectably di¡erent to wild-
type DPP IV (Tables 2 and 3).
3.3. Structural integrity of mutants
The possibility that e¡ects of mutations on enzyme activity
were mediated by overall structural defects was examined in
detail. Most mAbs to DPP IV, including EF6/B10, recognise
epitopes in the N-terminal residues 1^356 of DPP IV (Abbott
et al., 1999, submitted) [42,43]. ADA binding is in the putative
L propeller domain and is dependent on the tertiary structure
(Abbott et al., 1999, submitted) [44]. The DWVYEEE motif is
also in this region of human DPP IV. Immunocytochemistry
revealed that all point mutations bound to the anti-DPP IV
mAb EF6/B10 (Table 2). In addition, all mutants except Val-
202-Arg maintained binding to biotinylated ADA (Table 2)
and ADA-FITC (Fig. 3). Two-colour £ow cytometry demon-
strated that all mutants except Val-202-Arg achieved wild-
type levels of cell surface expression (Fig. 3). The Val-202-
Arg mutant produced much lower levels of DPP IV expres-
sion than wild-type (Table 2 and Fig. 3c) and failed to bind
ADA in a Western blot (not shown). When Val202 was re-
placed with the small uncharged residue alanine rather than
the charged residue arginine, there was no e¡ect on enzyme
activity, mAb EF6/B10 binding or ADA binding (Table 2 and
Fig. 3d). These data suggest that the Val-202-Arg mutation
signi¢cantly disrupted the secondary and/or tertiary structure.
This mutant was therefore omitted from further analysis. All
other mutations exhibited the same mobility as both puri¢ed
soluble recombinant DPP IV and wild-type DPP IV in West-
ern blots, indicating intact dimerisation (Fig. 4A). In addition,
an ADA overlay Western blot con¢rmed that all these mu-
tants bound ADA (Fig. 4B).
4. Discussion
In this study, we found that two single amino acid point
mutations, of glutamic acid residues Glu205 and Glu206 in the
predicted L propeller domain of DPP IV, did not detectably
alter the overall structure of the DPP IV protein but ablated
its catalytic activity. In contrast, point mutations of adjacent
residues did not detectably alter the catalytic activity. The
residues examined form a highly conserved seven amino acid
sequence motif DW(V/I/L)YEEE. We propose that a sub-
class of the POP family exists, the DPP IV-like gene family,
and this motif will be present in all members of this sub-
family. This motif is at a considerable distance in the primary
structure from the established Ser, Asp, His catalytic triad
that forms the charge relay system at the active site of DPP
IV and other serine proteases [45]. This is the ¢rst report of a
single amino acid point mutation outside the K/L hydrolase
fold of a POP enzyme that disrupts only proteolysis. As the
three dimensional structure of DPP IV is unknown, a mech-
anism for the role of these residues in proteolysis is not ob-
vious. However, based on our sequence alignment with POP
and a model of DPP IV (Abbott et al., 1999, submitted), we
propose that Glu205 and Glu206 are essential for substrate
entry into DPP IV.
Both natural and recombinant DPP IV glycoproteins form
Mr 150 kDa dimers. The dimer is catalytically active whereas
the monomer is not [46,47]. Therefore, failure to dimerise
could ablate DPP IV enzyme activity. However, all of the
mutants studied exhibited wild-type levels of dimerisation,
so it is very unlikely that Glu205 or Glu206 are essential for
dimerisation.
The three dimensional structure of pig POP has recently
been solved [12] and by examining the sequence and structure
of POP, we can suggest a position of the DWVYEEE motif in
the human DPP IV tertiary structure. As predicted by others
[6,10], POP contains a peptidase domain having an K/L hydro-
lase fold which contains the catalytic triad (Ser-Asp-His).
Table 3
Enzyme kinetic data for wild-type and mutant DPP IV expressed on live cells, 72 h after transfection, assayed in triplicate under an eight point
titration of the substrate Gly-Pro-toluene sulfonate (0.013^1.7 mM)
Mutation Vmax Km
Mean (vA405/min) S.D. Mean (mM) S.D.
DPP IV wild-type 0.0257 0.00055 0.458 0.02247
Trp-201-Tyr 0.0788 0.01888 0.779 0.22324
Val-202-Ala 0.1083 0.01333 0.763 0.13834
Tyr-203-Val 0.0117 0.00110 0.295 0.04375
Glu-204-Lys 0.0417 0.00298 0.972 0.11341
Glu-204-Gln 0.0485 0.00451 0.916 0.11758
Glu-205-Lys 0.0099 0.00144 2.542a 0.54840
Glu-206-Leu 0.0008 0.00035 0.739 0.70660
aSigni¢cantly di¡erent to wild-type DPP IV (P6 0.005).
Fig. 4. Western blots of transfected COS-7 cell preparations demon-
strated the structural integrity of the Glu-205-Lys and Glu-206-Leu
mutations that ablated enzyme activity. (A) Western blot of 8%
SDS-PAGE gel. The ¢rst two lanes contained two di¡erent quanti-
ties of puri¢ed soluble recombinant human DPP IV [40]. The other
lanes contain non-boiled cell extracts. All mutants showed the same
mobility as puri¢ed DPP IV, a 150 kDa dimer detected using anti-
DPP IV mAb 2A6. (B) Western blot of non-boiled COS cell ex-
tracts on an 8^12% SDS-PAGE gel (NuPage) showed that all mu-
tants bound ADA, detected by sequential incubations with ADA,
rabbit anti-ADA antiserum and then anti-rabbit HRP.
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However, the central tunnel of an unusual seven blade L pro-
peller domain covers the catalytic cleft formed by the K/L
hydrolase fold. This propeller domain is thought to make
POP an oligopeptidase by excluding large structured peptides
from occupying the catalytic pocket. In this fashion, the pro-
peller is thought to protect larger peptides and proteins from
proteolysis. The entrance to the POP catalytic pocket is in the
centre of the lower face of the L propeller. In POP, six
charged residues (Lys82, Glu134, His180, Asp242, Lys389 and
Lys390) surround the narrow pore at this entrance and can
be termed pore closing residues. It has been suggested that
the lining of the opening of this narrow pore by charged
£exible side chains allows for speci¢c substrate entry and
that this is a substrate-induced event [12].
Threading algorithms of human DPP IV have predicted
that the DWVYEEE motif forms part of an K helix whereas
physiochemical studies indicate that DPP IV contains more L
structure than predicted [48]. Similar threading queries and a
preliminary model of human DPP IV now predict this motif
to be part of a L strand and a loop on the inner surface of the
predicted L propeller (Abbott et al., 1999, submitted). A sim-
ilar sequence in pig POP, Gly129-Tyr130-Ala131-Phe132-Ser133-
Glu134-Asp135, aligns with the Asp200-Trp201-Val202-Tyr203-
Glu204-Glu205-Glu206 motif of human DPP IV. This motif in
pig POP is conserved amongst POPs of other species. In POP,
the residues Gly129-Tyr130-Ala131-Phe132 lie at the end of the
¢rst strand of the second blade while residues Ser133-Glu134-
Asp135 lie in the subsequent loop. In addition, as discussed
previously, Glu134 is a pore closing residue [12]. Assuming
that the POP structure is a prototype for DPP IV, the
Glu205 of DPP IV may be equivalent to Glu134 in POP. There-
fore, reversing or neutralising the charge at Glu205 or Glu206
may have ablated DPP IV enzyme activity by disallowing
substrate entry into the central tunnel of the L propeller.
The other residues of the conserved motif may have a role
in positioning these two glutamates in the pore. Interestingly,
the Glu-206-Leu substitution is found in X. laevis FAP. Un-
like human and mouse FAP [26,27], X. laevis FAP has not
been tested for dipeptidyl peptidase enzyme activity [41] and
perhaps, this protein is enzymatically inactive.
The enzyme activity of DPP IV has roles in HIV infection,
in£ammatory processes and immune responses [2,49^53]. In
order to design speci¢c DPP IV inhibitors and analogues for
use as therapeutics, it is essential to understand the mecha-
nism of DPP IV substrate speci¢city and cleavage in more
detail. Our structure-function data provide a novel perspective
on the requirements for proteolysis in the DPP IV-like gene
family. In particular, it pinpoints residues distant in primary
structure to the C-terminal catalytic triad residues that are
important for DPP IV enzyme activity. Crystallisation of
DPP IV will be required to determine the precise position
and nature of this motif in this family of enzymes.
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